Trial Profile
A phase I, randomized, double blind, placebo controlled, single-dose, rising dose cohort study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRO 140 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Leronlimab (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Adverse reactions
- Sponsors Progenics Pharmaceuticals
- 07 Oct 2005 New trial record.